Hikma Pharmaceuticals (CHIX:HIKL) Shares Outstanding (Basic Average): 220 Mil (As of Dec. 2025)


CHIX:HIKL Hikma Pharmaceuticals PLC CHIX:HIKL
80 GF Score
Price £15.11
GF Value £20.99
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Shares Outstanding (Basic Average)?

Hikma Pharmaceuticals CHIX:HIKL +1.96% 80 Shares Outstanding (Basic Average) is 220 Mil as of Dec. 2025. GuruFocus rates CHIX:HIKL with a GF Score™ of 80/100 and a GF Value™ of £20.99 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Hikma Pharmaceuticals's average basic shares outstanding for the quarter that ended in Dec. 2025 was 220 Mil.


Hikma Pharmaceuticals  (CHIX:HIKl) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Hikma Pharmaceuticals Shares Outstanding (Basic Average) Related Terms


Hikma Pharmaceuticals Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for Hikma Pharmaceuticals's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikma Pharmaceuticals Shares Outstanding (Basic Average) Chart

Hikma Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 231.00 223.73 220.86 221.33 220.59

Hikma Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 221.08 221.75 220.43 221.45 220.11
CHIX:HIKL
80GF Score
Hikma Pharmaceuticals PLC CHIX:HIKL
Shares Outstanding (Basic Average) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 220 Mil mean?
Hikma Pharmaceuticals (CHIX:HIKL) has a Shares Outstanding (Basic Average) of 220 Mil as of Dec. 2025. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' Shares Outstanding (Basic Average) too high?
Hikma Pharmaceuticals' current Shares Outstanding (Basic Average) is 220 Mil. Overall, Hikma Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Shares Outstanding (Basic Average) compare to ZTS and UTHR?
Hikma Pharmaceuticals' Shares Outstanding (Basic Average) of 220 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Drug Manufacturers company?
A good Shares Outstanding (Basic Average) depends on the Drug Manufacturers industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current Shares Outstanding (Basic Average) is 220 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (CHIX:HIKL) is currently considered Modestly Undervalued. The stock's GF Value™ is £20.99, compared to a current price of £15.11 — trading 28% below its estimated fair value. The current Shares Outstanding (Basic Average) is 220 Mil. Hikma Pharmaceuticals' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Hikma Pharmaceuticals (CHIX:HIKL), the current Shares Outstanding (Basic Average) is 220 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (CHIX:HIKL) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of £15.11 is trading 28% below its estimated GF Value™ of £20.99. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for CHIX:HIKL:

  • Shares Outstanding (Basic Average): 220 Mil
  • GF Value™: £20.99 vs. price of £15.11 (28% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the CHIX:HIKL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
80GF Score

Get the complete analysis for CHIX:HIKL

Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£15.11
Price
£20.99
GF Value